Further, Physical Characterization of Biopolymer Isolated from Seeds of Manilkara Zapota (Linn.) P. Royen Syn. with Potential Pharmaceutical Use
Journal: International Journal of PharmaO2 (IJPO) (Vol.3, No. 5)Publication Date: 2021-09-16
Authors : Sudarshan Singh Tanvi R Dodiya Rajesh Dodiya Sangeeta Singh Sunil B Bothara.;
Page : 0222-0229
Keywords : Manilkara zapota; Natural Polymer; Physical characterization; HPMC E5; Guar gum;
Abstract
Manilkara zapota (Linn.) P. Royen syn. a shrub belonging to family sapotaceae. The whole plant have been reported as a source of biomedicine. In our previous study we reported mucoadhesive charaterization of isolated gum from the seeds of Manilkara zapota. Here in, we further investigated the physical property of tablets including wetting time, water absorption ratio, mass degree of swelling, water uptake, mass loss, and in-vitro swelling developed using seed mucilage of Manilkara zapota fruit. The results of physical characterization indicated that the biopolymer possess similar bioadhesive property as compared to synthetic polymer used in study. The result showed that physical property of seeds mucilage is comparable to synthetic under the experimental conditions. Briefly, it could be concluded that the seed mucilage of M. zapota can be used as a pharmaceutical excipient in oral mucoadhesive drug delivery systems. Moreover, it has the potential to also replace existing synthetic mucoadhesive polymers upon further polymerization or chemical modifications.
Other Latest Articles
- An Overview: Trigonelle foenum graecum on Human Health
- Mupirocin Loaded Microemulsion Based Gel for Effective Treatment of Burns
- The Clinical Risk Management (CRM) Assessment at Dr. H. Abdul Moeloek Hospital, Regional Public Hospital in Lampung Province Indonesia, using Briner's CRM Instrument in 2020
- Emergency Perioperative Management of Cardiovascular Implantable Electronic Devices in Critical Trauma Patients
- Labor Analgesia when Neuraxial Anesthesia is Relatively Contraindicated: Comparison of Patient-Controlled Fentanyl and Intermittent Nalbuphine Boluses
Last modified: 2021-09-16 16:09:47